Location History:
- Pearland, TX (US) (2017)
- Bellaire, TX (US) (2022)
- Houston, TX (US) (2023)
Company Filing History:
Years Active: 2017-2023
Title: Shiaw-Yih Lin: Innovator in Cancer Treatment
Introduction
Shiaw-Yih Lin is a prominent inventor based in Pearland, TX (US). She has made significant contributions to the field of cancer treatment through her innovative research and patented methods. With a total of 3 patents, her work focuses on enhancing immunotherapy responses and improving cancer treatment strategies.
Latest Patents
Shiaw-Yih Lin's latest patents include groundbreaking methods for predicting cancer metastasis and improving immune therapy responses. One of her notable patents is titled "Replication stress response biomarkers for immunotherapy response." This patent outlines methods for increasing immune therapy response by analyzing the expression of genes associated with replication stress response. It also discusses the treatment of cancers using immune checkpoint inhibitors and/or MEK inhibitors. Another significant patent is "Gene signatures to predict drug response in cancer," which details methods for identifying and treating cancers that are DNA repair defective or sensitive to PARP inhibitors or platinum-based therapy. This patent emphasizes the treatment of such cancers with PARP inhibitor therapy or cisplatin.
Career Highlights
Shiaw-Yih Lin is affiliated with the University of Texas System, where she continues her research and development in cancer therapies. Her work has been instrumental in advancing the understanding of cancer treatment and the role of genetic factors in therapy responses.
Collaborations
Shiaw-Yih Lin collaborates with esteemed colleagues, including Daniel McGrail and Gordon B Mills, to further her research initiatives and enhance the impact of her inventions.
Conclusion
Shiaw-Yih Lin's innovative contributions to cancer treatment through her patented methods highlight her dedication to improving patient outcomes. Her work continues to pave the way for advancements in immunotherapy and cancer research.